Therapies in non-alcoholic steatohepatitis ( NASH )

Abstract

The hallmark of non- alcoholic fatty liver disease ( NAFLD ) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non- alcoholic fatty liver, NAFL ) or accompanied by evidence of inflammation and cell injury with or without fibrosis (non- alcoholic steatohepatitis, NASH ). NASH , the more aggressive form of NAFLD , may progress to cirrhosis and hepatocellular carcinoma. Since NASH is estimated to overtake hepatitis C virus infection as the leading cause of liver transplantation in the US in the coming decade, and there are no current FDA – approved therapies for this disease, the need to find appropriate therapeutic targets is now more urgent than ever before. Diet and other lifestyle modifications have always been difficult to maintain and this approach alone has not slowed the rising tide of the disease. While the results of traditional therapies such as vitamin E and pioglitazone have been significant for steatosis and inflammation, they have had no effect on fibrosis, which is the strongest indicator of mortality in this condition. However, the understanding of the pathogenesis and progression of NASH has evolved and several promising novel therapies to target and possibly reverse fibrosis are being evaluated, making the future outlook of NASH therapy more optimistic.

 

K E Y W O R D S

farnesoid X receptor ( FXR ) , glucagon-like peptide ( GLP -1) agonist , non-alcoholic fatty liver disease ( NAFLD ) , non-alcoholic steatohepatitis ( NASH ) , peroxisome proliferator-activator receptor ( PPAR ) agonists , ROS (reactive oxygen species)

About Speaker

Arun SANYAL

Professor of Medicine

USA

City: Richmond

Institution: Virginia Commonwealth University

Contact: ajsanyal@vcu.edu


Biography of Arun SANYAL

Dr. Sanyal’s is a specialist in chronic liver disease and its outcomes. He is the Executive Director, Education Core, Clinical Center for Translational Research, VCU. He served as a chair of the National Institutes of Health (NIH) NASH Research Network and is the current Chair of the Liver Study Section at NIH. He is the Academic and Steering Committee Co-Chair of The Liver Forum. His research into liver diseases has led to recommendations related to variceal hemorrhage, ascites, hepatorenal syndrome, hepatic encephalopathy, and NASH. He is the American Liver Foundation 2017 Distinguished Scientific Award Winner Recipient.

View more